Clinical Trials Directory

Trials / Completed

CompletedNCT00399763

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

A Randomized, Placebo-controlled Trial of Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder (SUD)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
70 (actual)
Sponsor
Denver Health and Hospital Authority · Academic / Other
Sex
All
Age
12 Years – 19 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

Detailed description

Evidence-based psychosocial treatments have recently been developed. However, very little data exist on the use of pharmacotherapy for adolescents SUD (Substance Use Disorder). One promising pharmacotherapy approach is to treat co-occuring psychiatric disorders. A common co-occurring disorder in adolescent SUD is attention-deficit/hyperactivity disorder (ADHD). Fortunately, new ADHD medications, such as atomoxetine, that do not have addictive potential are now available. However, all controlled studies of atomoxetine have specifically excluded teens with SUD. Therefore, little data exist on the safety and efficacy of the medication in this population. This research project will address the important research gap with the specific aim: to conduct a randomized, placebo-controlled trial of atomoxetine for ADHD in teens with SUD.

Conditions

Interventions

TypeNameDescription
DRUGAtomoxetineHalf of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
DRUGPlaceboHalf of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder

Timeline

Start date
2005-09-01
Primary completion
2008-02-01
Completion
2008-02-01
First posted
2006-11-15
Last updated
2015-07-08
Results posted
2015-07-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00399763. Inclusion in this directory is not an endorsement.